无创心血管影像在类风湿关节炎心血管风险评估中的作用:现状与未来方向
本综述评估类风湿关节炎(RA)患者心血管疾病(CVD)的风险评估现状,并探讨无创影像技术未来如何改善风险分层。RA患者CVD风险高于一般人群,传统临床CVD风险算法对RA患者尤其中等风险者估计不佳。颈动脉超声对临床算法评估为中等CV死亡风险者有合理证据支持使用,而心血管磁共振和CT等新技术尚缺乏硬终点纵向数据。
要点
- RA患者CVD风险高于一般人群,传统风险算法对RA尤其中等风险者估计不佳。
- 颈动脉超声对临床算法评估为中等CV死亡风险者有合理证据支持使用。
- 心血管磁共振和CT有潜力进一步改善风险分层,但缺乏硬终点纵向数据。
核心结论
- 无创影像技术可能改善RA患者的心血管风险分层,但当前针对RA患者的预后数据非常有限,不足以指导临床使用这些技术进行风险分层。
研究设计与样本
- 本综述评估RA患者CVD风险评估现状及无创影像模态在未来改善风险分层中的潜在作用。
主要发现
- RA患者CVD风险高于一般人群,且风险特征与一般人群不同,传统临床CVD风险算法对RA患者尤其中等风险者估计不佳。
- RA与CV死亡风险增加相关,主要归因于动脉粥样硬化性疾病,但RA还与其他多种疾病过程相关,进一步增加CV死亡。
- 颈动脉超声对临床CVD风险算法评估为中等CV死亡风险者有合理证据支持使用。
- 心血管磁共振和CT等较新影像技术有潜力进一步改善风险分层,但目前缺乏硬CVD结局的纵向数据。
关键数值与推荐
- 欧洲指南推荐对高和极高CV风险患者进行CV风险分层以启动预防治疗。
- 理想情况下应在诊断后立即进行CV风险评估,并作为长期患者管理的一部分。
临床怎么用
- 对RA患者应遵循欧洲指南推荐进行CV风险分层,尤其高和极高风险者,以启动预防治疗。
- 对临床CVD风险算法评估为中等CV死亡风险者,可考虑使用颈动脉超声辅助风险分层。
- 心血管磁共振和CT等新技术目前不应用于临床风险分层决策,因缺乏硬终点纵向数据。
局限性
- 目前针对RA患者的无创影像技术预后数据非常有限。
- 心血管磁共振和CT等较新影像技术缺乏硬CVD结局的纵向数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review assesses the risk assessment of cardiovascular disease (CVD) in rheumatoid arthritis (RA) and how non-invasive imaging modalities may improve risk stratification in future. RA is common and patients are at greater risk of CVD than the general population. Cardiovascular (CV) risk stratification is recommended in European guidelines for patients at high and very high CV risk in order to commence preventative therapy. Ideally, such an assessment should be carried out immediately after diagnosis and as part of ongoing long-term patient care in order to improve patient outcomes. The risk profile in RA is different from the general population and is not well estimated using conventional clinical CVD risk algorithms, particularly in patients estimated as intermediate CVD risk. Non-invasive imaging techniques may therefore play an important role in improving risk assessment. However, there are currently very limited prognostic data specific to patients with RA to guide clinicians in risk stratification using these imaging techniques. RA is associated with increased risk of CV mortality, mainly attributable to atherosclerotic disease, though in addition, RA is associated with many other disease processes which further contribute to increased CV mortality. There is reasonable evidence for using carotid ultrasound in patients estimated to be at intermediate risk of CV mortality using clinical CVD risk algorithms. Newer imaging techniques such as cardiovascular magnetic resonance and CT offer the potential to improve risk stratification further; however, longitudinal data with hard CVD outcomes are currently lacking.
引用
- Fent GJ, Greenwood JP, Plein S, et al. The role of non-invasive cardiovascular imaging in the assessment of cardiovascular risk in rheumatoid arthritis: where we are and where we need to be. Ann Rheum Dis. 2016. PMID: 27895040. doi:10.1136/annrheumdis-2016-209744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。